Loading...
Market
Where will BEAM-101 be approved by end of 2025?
2
Resolution / Starting Odds
US only • 25%
US and EU • 25%
US, EU, and China • 25%
None • 25%
Approval announcements from respective regulatory bodies (FDA, EMA, NMPA)
Story
Beam Therapeutics' BEAM-101 Shows Superior Results at ASH 2024, Stock Rises
Dec 9, 2024, 12:57 PM
Beam Therapeutics Inc. has reported promising clinical data for its sickle cell gene therapy, BEAM-101, at the American Society of Hematology (ASH) 2024 conference. The therapy has shown an average of 64-65% fetal hemoglobin (HbF) levels in patients, significantly higher than its competitors Reni-cel and Casgevy. BEAM-101's efficient manufacturing process allows for fewer mobilization cycles, with an average of 1.4 cycles, compared to Reni-cel's 4.6 and Casgevy's 4.7. This efficiency could potentially expand the eligible patient population for gene editing therapies. Additionally, Beam's approach includes a novel conditioning regimen using an anti-CD117 antibody, aiming to reduce toxicity and increase the feasibility of the treatment. The company's stock saw a 6.5% increase following the announcement, reflecting positive market sentiment towards the potential of BEAM-101.
View original story
Similar markets
Lung Cancer • 25%
Breast Cancer • 25%
Colorectal Cancer • 25%
Other • 25%
Only in the US • 25%
Only in the EU • 25%
In both US and EU • 25%
In US, EU, and Japan • 25%
Approved • 25%
Not Approved • 25%
Approval Pending • 25%
Withdrawn • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Safety warning update • 25%
Clinical trial halt • 25%
No action • 25%
Other action • 25%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Yes • 50%
No • 50%
Mesothelioma • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Other • 25%
Approved in USA only • 25%
Approved in EU only • 25%
Approved in both USA and EU • 25%
Not approved in USA or EU • 25%
Universal gene therapy • 33%
Mutation-specific gene therapy • 33%
No approval • 34%